MedTrace Logo

Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer

NCT05510895 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2025-10-01

No results posted yet for this study

Summary

AIO-KRK-0420 NeoBRAF is a single arm, multicenter, phase II trial with neoadjuvant encorafenib, binimetinib and cetuximab for patients with BRAF V600E mutated/pMMR localized colorectal cancer.

Conditions

Interventions

DRUG

Binimetinib

Triplet combination administered neoadjuvant and adjuvant, depending on TRG

Sponsors & Collaborators

  • Pierre Fabre Pharma GmbH

    collaborator INDUSTRY

  • Merck Serono GmbH, Germany

    collaborator INDUSTRY

  • Universitätsklinikum Hamburg-Eppendorf

    collaborator OTHER

  • AIO-Studien-gGmbH

    lead OTHER

Principal Investigators

  • Alexander Stein, Prof. Dr. · Hämatologisch-Onkologische Praxis Eppendorf, 20249 Hamburg, Germany

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2024-07-31
Completion
2025-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05510895 on ClinicalTrials.gov